Quectel Launches High Performance Single-Band GNSS Positioning Module LC76G With Ultra-low Power Consumption
20.6.2022 15:30:00 EEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announced the release of its LC76G module, a single-band compact GNSS module featuring fast and accurate location performance as well as ultra-low power consumption. The LC76G has already entered mass production with sufficient supply to meet the needs of the global positioning market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220620005121/en/
Quectel LC76G module, a single-band compact GNSS module featuring fast and accurate location performance as well as ultra-low power consumption
Based on the Airoha AG3352 platform, the LC76G can concurrently receive and process signals from all constellations (GPS, GLONASS, BeiDou, Galileo and QZSS), which in combination with the support of SBAS greatly increases the number of visible satellites and enhances positioning accuracy. The LC76G module can receive signals from up to 47 satellites and achieve 1.5m (CEP50 open-sky) positioning accuracy representing a 40% improvement over previous generations of devices.
Available in a cost-optimized version as well as a low-power version, the LC76G low-power version consumes less than 9mA @3V with all 4 constellations enabled allowing for a 72% reduction in power required than previously possible.
This makes the LC76G extremely attractive for battery operated devices such as wearable personal trackers, wildlife and livestock tracking, Toll tags, portable container trackers as well as a host of traditional markets such as Shared Mobility and low-cost asset trackers.
Featuring an internal SAW filter and integrated LNA, the LC76G can be connected directly to a passive patch antenna and provides filtering against unwanted interference ensuring excellent performance even while driving through dense urban canyons.
Integrated AGNSS technology EPO™, is supported on the LC76G module and reduces the time to first fix (TTFF) with a hot start taking less than 1 second, a warm start within 2 seconds, while the cold start can obtain accurate tracking fixes within 15 seconds. The faster GNSS fixes make it possible to use accurate positioning and navigation services anytime and anywhere with a smaller power budget than previously possible.
While EPO requires manual download of predicted orbits, the LC76G also supports EASY™ (Embedded Assist System) where predicted orbit information is collected directly from the Satellites and provides for up to 3 days of accelerated fixes.
Both EPO and Easy™ are available for each constellation allowing for faster TTFF and reduced dependency on any particular constellation.
Featuring an LCC form factor and an ultra-compact size of 10.1mm × 9.7mm ×2.4mm, the footprint of the LC76G is compatible with other industry solutions as well as Quectel’s legacy L76 and L76-LB modules, allowing for a smooth migration of existing designs to the latest low power GNSS technology.
In addition, Quectel offers a wide range of off-the-shelf and customized high-performance antennas which boost wireless connectivity significantly. Quectel’s LC76G can be combined with a selection of GNSS L1 antennas to enable various positioning requirements. Customized connector type and cable length as well as comprehensive antenna design and test support are also available to facilitate customer product development.
The LC76G will be on display at Embedded World Nuremberg on Booth No 171, Hall 5, June 21- 23 2022.
About Quectel:
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS and WiFi/BT modules, antennas and IoT connectivity. Listed on the Shanghai Stock Exchange (603236.SS), our international leadership is devoted to advancing IoT across the globe.
For more information: www.Quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220620005121/en/
Contact information
Ashley Liu
media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom